These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31585260)

  • 1. Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
    Ding HW; Yu L; Bai MX; Qin XC; Song MT; Zhao QC
    Bioorg Chem; 2019 Dec; 93():103283. PubMed ID: 31585260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
    Yang YQ; Chen H; Liu QS; Sun Y; Gu W
    Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and synthesis of 2-amino-1-methyl-1H-imidazol-4(5H)-ones as GPCR ligands; an approach to develop breast cancer drugs via GPCR associated PAR1 and PI3Kinase inhibition mechanism.
    Ashok SR; Shivananda MK; Manikandan A; Chandrasekaran R
    Bioorg Chem; 2019 May; 86():641-651. PubMed ID: 30822721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
    Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
    J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of new thieno[2,3-
    Elmenier FM; Lasheen DS; Abouzid KAM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):315-332. PubMed ID: 34955086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3Kα.
    Yin Y; Zhou Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
    Bioorg Chem; 2019 Nov; 92():103238. PubMed ID: 31499259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity.
    Tian C; Yang C; Wu T; Lu M; Chen Y; Yang Y; Liu X; Ling Y; Deng M; Jia Y; Zhou Y
    Bioorg Med Chem Lett; 2021 Sep; 48():128271. PubMed ID: 34284105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
    Zhang K; Lai F; Lin S; Ji M; Zhang J; Zhang Y; Jin J; Fu R; Wu D; Tian H; Xue N; Sheng L; Zou X; Li Y; Chen X; Xu H
    J Med Chem; 2019 Aug; 62(15):6992-7014. PubMed ID: 31117517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.
    Alkahtani HM; Abbas AY; Wang S
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1317-21. PubMed ID: 22225635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
    Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
    Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
    Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
    Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
    Wang Y; Tortorella M
    Eur J Med Chem; 2022 Jan; 228():114039. PubMed ID: 34894440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)- benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα).
    Bilginer S; Bardaweel SK; Sabbah DA; Gul HI
    Anticancer Agents Med Chem; 2021; 21(6):716-724. PubMed ID: 32767959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
    Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
    Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation.
    Yang C; Lu M; Chen Y; Xiang R; Qiu T; Jia Y; Yang Y; Liu X; Deng M; Ling Y; Zhou Y
    Bioorg Chem; 2021 Dec; 117():105405. PubMed ID: 34649154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
    Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
    Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.